Navigation Links
Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show
Date:12/13/2007

F="http://today.msnbc.msn.com" target="_new">http://today.msnbc.msn.com, and scroll through the "Video from TODAY" section. Click on "Understanding Epilepsy."

For additional information on CURE, contact Michelle Marciniak or visit http://www.CUREepilepsy.org.


'/>"/>
SOURCE CURE
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
2. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Former State Representative Terry Parke Joins Secure Services Corp.
5. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
6. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, & Countrys Top Drug Treatment CEO Barry Karlin to Keynote Palm Beach, FL National Moment Of Change Intervention Conference:
7. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
8. Former HHS Secretary Dr. Louis Sullivan, Lt. Gov. Cagle Address Need to Improve Quality of Patient Care
9. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
10. Nobel Honors 3 Former March of Dimes Prize Recipients
11. Over one-third of former American football players had sexual relations with men, study says
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 1EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 3Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 1Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 2Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 3New Fastrack Technology Improves Productivity 55477 1New Fastrack Technology Improves Productivity 55477 2New Fastrack Technology Improves Productivity 55477 3
Other Medicine Technology:Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 2Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 3Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 4